136 related articles for article (PubMed ID: 34540189)
21. Knockdown of long noncoding RNA colorectal neoplasia differentially expressed inhibits hepatocellular carcinoma progression by mediating the expression of nuclear autoantigenic sperm protein.
Zhu Y; Li B; Xu G; Han C; Xing G
Oncol Rep; 2021 Dec; 46(6):. PubMed ID: 34633056
[TBL] [Abstract][Full Text] [Related]
22. High expression of lnc-CRNDE presents as a biomarker for acute myeloid leukemia and promotes the malignant progression in acute myeloid leukemia cell line U937.
Wang Y; Zhou Q; Ma JJ
Eur Rev Med Pharmacol Sci; 2018 Feb; 22(3):763-770. PubMed ID: 29461608
[TBL] [Abstract][Full Text] [Related]
23. The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling.
Han P; Li JW; Zhang BM; Lv JC; Li YM; Gu XY; Yu ZW; Jia YH; Bai XF; Li L; Liu YL; Cui BB
Mol Cancer; 2017 Jan; 16(1):9. PubMed ID: 28086904
[TBL] [Abstract][Full Text] [Related]
24. Long noncoding RNA CRNDE stabilized by hnRNPUL2 accelerates cell proliferation and migration in colorectal carcinoma via activating Ras/MAPK signaling pathways.
Jiang H; Wang Y; Ai M; Wang H; Duan Z; Wang H; Zhao L; Yu J; Ding Y; Wang S
Cell Death Dis; 2017 Jun; 8(6):e2862. PubMed ID: 28594403
[TBL] [Abstract][Full Text] [Related]
25. LncRNA colon cancer-associated transcript 1 (CCAT1) promotes proliferation and metastasis of ovarian cancer via miR-1290.
Lai XJ; Cheng HF
Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):322-328. PubMed ID: 29424889
[TBL] [Abstract][Full Text] [Related]
26. Long non-coding RNA CRNDE may be associated with poor prognosis by promoting proliferation and inhibiting apoptosis of cervical cancer cells through targeting PI3K/AKT.
Yang HY; Huang CP; Cao MM; Wang YF; Liu Y
Neoplasma; 2018 Nov; 65(6):872-880. PubMed ID: 30334449
[TBL] [Abstract][Full Text] [Related]
27. lncRNA CRNDE promotes the proliferation and metastasis by acting as sponge miR-539-5p to regulate POU2F1 expression in HCC.
Li Z; Wu G; Li J; Wang Y; Ju X; Jiang W
BMC Cancer; 2020 Apr; 20(1):282. PubMed ID: 32252678
[TBL] [Abstract][Full Text] [Related]
28. LncRNA CRNDE is a biomarker for clinical progression and poor prognosis in clear cell renal cell carcinoma.
Ding C; Han F; Xiang H; Xia X; Wang Y; Dou M; Zheng J; Li Y; Xue W; Ding X; Tian P
J Cell Biochem; 2018 Dec; 119(12):10406-10414. PubMed ID: 30129055
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of the long non-coding RNA SPRY4-IT1 indicates a poor prognosis and promotes tumorigenesis in ovarian cancer.
Li H; Liu C; Lu Z; Chen L; Wang J; Li Y; Ma H
Biomed Pharmacother; 2017 Apr; 88():529-534. PubMed ID: 28129625
[TBL] [Abstract][Full Text] [Related]
30. Long noncoding RNA HOTTIP is a significant indicator of ovarian cancer prognosis and enhances cell proliferation and invasion.
Zou T; Wang PL; Gao Y; Liang WT
Cancer Biomark; 2019; 25(2):133-139. PubMed ID: 30452402
[TBL] [Abstract][Full Text] [Related]
31. LncRNA CRNDE acts as an oncogene in cervical cancer through sponging miR-183 to regulate CCNB1 expression.
Bai X; Wang W; Zhao P; Wen J; Guo X; Shen T; Shen J; Yang X
Carcinogenesis; 2020 Mar; 41(1):111-121. PubMed ID: 31605132
[TBL] [Abstract][Full Text] [Related]
32. Upregulation of long non‑coding RNA CCEPR is associated with poor prognosis and contributes to the progression of ovarian cancer through regulating the Wnt/β‑catenin signaling pathway.
Chen Z; Zhu Y; Fan X; Liu Y; Feng Q
Mol Med Rep; 2020 Apr; 21(4):1950-1958. PubMed ID: 32319633
[TBL] [Abstract][Full Text] [Related]
33. LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma.
Xie SC; Zhang JQ; Jiang XL; Hua YY; Xie SW; Qin YA; Yang YJ
Cell Death Dis; 2020 Aug; 11(8):676. PubMed ID: 32826865
[TBL] [Abstract][Full Text] [Related]
34. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
Fang L; Wang H; Li P
Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
[TBL] [Abstract][Full Text] [Related]
35. The putative oncogene, CRNDE, is a negative prognostic factor in ovarian cancer patients.
Szafron LM; Balcerak A; Grzybowska EA; Pienkowska-Grela B; Podgorska A; Zub R; Olbryt M; Pamula-Pilat J; Lisowska KM; Grzybowska E; Rubel T; Dansonka-Mieszkowska A; Konopka B; Kulesza M; Lukasik M; Kupryjanczyk J
Oncotarget; 2015 Dec; 6(41):43897-910. PubMed ID: 26556866
[TBL] [Abstract][Full Text] [Related]
36. lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-κB Signaling Pathway.
Zhao Y; Hong L
Cancer Biother Radiopharm; 2021 Mar; 36(2):202-210. PubMed ID: 33156701
[No Abstract] [Full Text] [Related]
37. Long non-coding RNA RP11-552M11.4 promotes cells proliferation, migration and invasion by targeting BRCA2 in ovarian cancer.
Huang K; Geng J; Wang J
Cancer Sci; 2018 May; 109(5):1428-1446. PubMed ID: 29478268
[TBL] [Abstract][Full Text] [Related]
38. LncRNA CRNDE is activated by SP1 and promotes osteosarcoma proliferation, invasion, and epithelial-mesenchymal transition via Wnt/β-catenin signaling pathway.
Ding Q; Mo F; Cai X; Zhang W; Wang J; Yang S; Liu X
J Cell Biochem; 2020 Jun; 121(5-6):3358-3371. PubMed ID: 31898343
[TBL] [Abstract][Full Text] [Related]
39. LncRNA CRNDE promotes hepatocellular carcinoma cell proliferation, invasion, and migration through regulating miR-203/ BCAT1 axis.
Ji D; Jiang C; Zhang L; Liang N; Jiang T; Yang B; Liang H
J Cell Physiol; 2019 May; 234(5):6548-6560. PubMed ID: 30230527
[TBL] [Abstract][Full Text] [Related]
40. Knockdown of LncRNA CRNDE suppresses proliferation and P-glycoprotein-mediated multidrug resistance in acute myelocytic leukemia through the Wnt/β-catenin pathway.
Kang Y; Zhang S; Cao W; Wan D; Sun L
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32426817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
